{"id":61974,"date":"2025-10-06T07:02:33","date_gmt":"2025-10-06T05:02:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/"},"modified":"2025-10-06T07:02:33","modified_gmt":"2025-10-06T05:02:33","slug":"ignota-labs-acquires-kronoss-clinical-pipeline","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/","title":{"rendered":"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline"},"content":{"rendered":"
\n

\nKronos, once valued at $3.5B, Had Two Phase 2 Stage Assets<\/i><\/p>\n

CAMBRIDGE, England–(BUSINESS WIRE)–Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos\u2019s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, SYK inhibitors. Kronos\u2019 valuation peaked at $3.5 billion after its IPO; however, it failed to progress its assets past Phase 2 trials and subsequently ceased operations. Given the challenges relating to safety and clinical positioning, Ignota Labs saw promise in the clinical portfolio and has acquired Kronos\u2019s clinical IP in full.<\/p>\n

<\/a>
<\/a><\/p>\n

\nIgnota Labs combines cheminformatics and bioinformatics in its AI platform, SAFEPATH, to identify the root causes of safety issues and improve safety while maintaining therapeutic effectiveness. Ignota\u2019s proprietary process will now assess the Kronos assets to identify the issue, solve the causes of toxicity, and develop the drug clinically and commercially to get it to patients.<\/p>\n

\nSam Windsor, Co-Founder and CEO at Ignota Labs, said: \u201cWe are acquiring assets that have demonstrated therapeutic effect, but failed in their development and were shelved despite tens of millions of dollars already invested in them. This is where Ignota Labs come in: unlocking value by turning around failing drugs so that they can quickly get back into clinical trials and bring fresh hope to the patients waiting for these drugs.\u201d<\/p>\n

\nBlood cancers and autoimmune disorders remain large, underserved markets. Chronic lymphocytic leukaemia (CLL) is an $8 billion market globally, and immune thrombocytopenia purpura (ITP) represents a $1.5 billion opportunity. By reviving these clinical assets, Ignota Labs is uniquely positioned to address these substantial patient and market needs.<\/p>\n

\nDr. Jordan Lane, Co-Founder and Chief Scientific Officer, said: \u201cThese drugs are desperately needed. Both CKD9 inhibitors and SYK inhibitors have shown clinical benefit to patients. By in-licensing these drugs, we are uniquely placed to bring these best-in-class drugs to patients with diseases that desperately need them.\u201d<\/p>\n

\nAbout Ignota Labs<\/b><\/p>\n

\nIgnota Labs turns around promising but failing drugs, bringing new life to abandoned projects and new hope to patients. In preclinical and clinical studies, safety assessments typically reveal what<\/i> went wrong\u2014such as liver damage or heart issues\u2014but fail to explain why<\/i> these issues occurred, or how<\/i> they might be mitigated. SAFEPATH is a first-of-its-kind AI platform that combines advanced machine learning models with a multimodal data approach to enable a deep understanding of toxicity mechanisms, and offers actionable insights to facilitate drug turnaround. The clinical stage company was founded by Cambridge researchers and pharmaceutical consultants, and investors include AIX Ventures, Montage Ventures, and Modi Ventures.<\/p>\n

\nFor more information, visit www.ignotalabs.ai<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact: hailey@commplicated.com<\/a> \/ +44 07480 559199<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Kronos, once valued at $3.5B, Had Two Phase 2 Stage Assets CAMBRIDGE, England–(BUSINESS WIRE)–Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos\u2019s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, SYK inhibitors. Kronos\u2019 valuation peaked at $3.5 billion after its IPO; however, it failed to progress its assets past … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61974","6":"format-standard","7":"category-industry"},"yoast_head":"\nIgnota Labs Acquires Kronos\u2019s Clinical Pipeline - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Kronos, once valued at $3.5B, Had Two Phase 2 Stage Assets CAMBRIDGE, England–(BUSINESS WIRE)–Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos\u2019s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, SYK inhibitors. Kronos\u2019 valuation peaked at $3.5 billion after its IPO; however, it failed to progress its assets past ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T05:02:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251005158956\/en\/2599359\/22\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline\",\"datePublished\":\"2025-10-06T05:02:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/\"},\"wordCount\":438,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251005158956\\\/en\\\/2599359\\\/22\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/\",\"name\":\"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251005158956\\\/en\\\/2599359\\\/22\\\/Logo.jpg\",\"datePublished\":\"2025-10-06T05:02:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251005158956\\\/en\\\/2599359\\\/22\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251005158956\\\/en\\\/2599359\\\/22\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ignota-labs-acquires-kronoss-clinical-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline - Pharma Trend","og_description":"Kronos, once valued at $3.5B, Had Two Phase 2 Stage Assets CAMBRIDGE, England–(BUSINESS WIRE)–Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos\u2019s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, SYK inhibitors. Kronos\u2019 valuation peaked at $3.5 billion after its IPO; however, it failed to progress its assets past ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-06T05:02:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251005158956\/en\/2599359\/22\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline","datePublished":"2025-10-06T05:02:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/"},"wordCount":438,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251005158956\/en\/2599359\/22\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/","url":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/","name":"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251005158956\/en\/2599359\/22\/Logo.jpg","datePublished":"2025-10-06T05:02:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251005158956\/en\/2599359\/22\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251005158956\/en\/2599359\/22\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ignota-labs-acquires-kronoss-clinical-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ignota Labs Acquires Kronos\u2019s Clinical Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61974"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61974\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}